Weekly risedronate in kidney transplant patients with osteopenia

Transplant International

Volumn 20, Issue 8, 2007, Pages 708-711

  Torregrosa, José Vicente ^a   Fuster, David ^a   Pedroso, Sofía ^b   Diekmann, Fritz ^a   Campistol, Josep María ^a   Rubí, Sebastià ^a   Oppenheimer, Federico ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

Bisphosphonates; Osteoporosis; Renal transplantation

Indexed keywords

ALKALINE PHOSPHATASE; CALCIUM; CALCIUM CARBONATE; COLECALCIFEROL; CREATININE; CYCLOSPORIN A; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PARATHYROID HORMONE; PHOSPHORUS; RISEDRONIC ACID; STEROID; TACROLIMUS; VITAMIN D;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ARTICLE; BONE DENSITY; BONE PAIN; BONE RADIOGRAPHY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DUAL ENERGY X RAY ABSORPTIOMETRY; FEMALE; FOLLOW UP; FRACTURE; HUMAN; INCIDENCE; INTERVIEW; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; OSTEOPENIA; PAIN ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SURGICAL PATIENT; X RAY ANALYSIS;

ADMINISTRATION, ORAL; ADOLESCENT; ADULT; AGED; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DISEASES, METABOLIC; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; ETIDRONIC ACID; FEMALE; FOLLOW-UP STUDIES; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 34347385818     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/j.1432-2277.2007.00501.x     Document Type: Article

References (11)

1. Lukert BP, Raisz LG. Corticosteroid-induced osteoporosis: pathogenesis and management. Ann Intern Med 1990 112: 352.
2. Julian BA, Laskow DA, Dubovsky J, Dubovsky EV, Curtis JJ, Quarles LD. Rapid loss of vertebral mineral density after renal transplantation. N Eng J Med 1991 325: 544.
3. Pichette V, Bonnardeaux A, Prudhomme L, Gagne M, Cardinal J, Ouimet D. Long-term bone loss in kidney transplant recipients: a cross-sectional and longitudinal study. Am J Kidney Dis 1996 28: 105.
4. Torregrosa JV, Campistol JM, Motesinos M, Pons F, Martinez-Osaba MJ. Evolution of bone mineral density after renal transplantation: related factors. Nephrol Dial Transplant 1995 10: S111.
5. Brandenburg VM, Westenfeld R, Ketteler M. The fate of bone loss after renal transplantation. J Nephrol 2004 17: 190.
6. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. Br Med J 1996 312: 1254.
7. Rodan GA, Fleisch HA. Bisphosphonates: mechanisms of action. J Clin Invest 1996 97: 2692.
8. Adachi J, Cranney A, Goldsmith CH, et al. Intermittent cyclic therapy with etidronate in the prevention of corticosteroid induced bone loss. J Rheumatol 1994 21: 1922.
9. Campistol JM, Holt DW, Epstein S, Gioud-Paquet M, Rutault K, Burke JT, the Sirolimus European Renal Transplant Study Group. Bone metabolism in renal transplant patients treated with cyclosporine or sirolimus. Transpl Int 2005 18: 1028.
10. Cruz DN, Brickel HM, Wysolmerski JJ. Treatment of osteoporosis and osteopenia in log-term renal transplant patients with alendronate. Am J Transplant 2002 2: 62.
11. Torregrosa JV, Moreno A, Gutierrez A, Vidal S, Oppenheimer F. Alendronate for treatment of renal transplant patients with osteoporosis. Transplant Proc 2003 35: 1383.